As China embraces AI, only 24% of US pharma execs bet on it for drug-making

Pharmaceutical companies have embraced artificial intelligence in drug research almost universally, yet few company executives expect AI to actually make drugs succeed, according to a Citi survey released on Tuesday. “The biggest risk to the AI-powered drug discovery thesis is not that AI fails to accelerate discovery,” said John Yung, head of Asia healthcare research at the US investment bank. “The stronger risk is that acceleration does not translate into better drugs or higher probability of...